Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
107 participants
OBSERVATIONAL
2026-02-28
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognosis Predicting of CRC Patients Based on Morphology and Molecular Biomaker of CTC
NCT04912882
Diagnosis, Treatment, and Prevention of Colorectal Cancer Amid Abnormal Lipid Metabolism
NCT06886022
Blood and Tissue Sample Collection for Future Colon Cancer Biomarker Studies in Patients Undergoing Colonoscopy
NCT00897403
Microbiome and Colorectal Cancer Recurrence
NCT07057076
Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
NCT07068529
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All genders, races, and ethnicities.
* Aged greater or equal to 18 years of age.
* Ability to understand and the willingness to sign a written informed consent form.
* Diagnosed with a colon adenocarcinoma or presumed adenocarcinoma in which surgical resection is recommended.
* Have a planned surgical resection of the colon adenocarcinoma at the University of Chicago Comprehensive Cancer Center.
* Reside within 150 miles of the University of Chicago Comprehensive Cancer Center.
Exclusion Criteria
* Intravenous or oral antibiotic exposure within 30 days of surgery to treat an infection.
* Prebiotic exposure within 30 days of surgery.
* History of neoadjuvant chemotherapy/radiation to treat the primary colon adenocarcinoma.
* History of chemotherapy/radiation to treat a separate malignancy within the last 6 months.
* History or current ileostomy or colostomy.
* Allergy to perioperative medications (oral neomycin/metronidazole for preoperative bowel preparation, intraoperative prophylactic intravenous cefoxitin).
* Patients who are pregnant.
* Patients with a history of inflammatory bowel disease.
* Patients with a history of bariatric surgery.
* History of eating disorders.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Diego
OTHER
Midwestern University
OTHER
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benjamin P Shogan
Role: PRINCIPAL_INVESTIGATOR
University of Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB25-0833
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.